| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of VU0359595 is phospholipase D1 (PLD1). It shows >1700-fold selectivity for PLD1 over PLD2 (IC50 of 6.4 μM). PLD1 is a key enzyme in cell signaling that produces phosphatidic acid, a lipid second messenger involved in cell proliferation and survival.
|
|---|---|
| ln Vitro |
VU0359595 (5, 50, 500, and 5000 nM) suppresses astrocyte basal proliferation as well as FCS/IGF-1-stimulated proliferation [2]. VU0359595 (5, 50, and 500 nM; 30 min) decreases mitogen-stimulated PLD activity in astrocytes in a concentration-dependent manner, but it has no effect on basal PLD activity [2]. Retinal pigment epithelium (RPE) cells' synthesis of [3H]-phosphatidylethanol (PEth) is stimulated by high glucose (33 mM), although this effect is substantially mitigated by VU0359595 (0.15 μM; 1 hour prior to and 4 hours during high glucose treatment) [3]. In LPS-induced (10 μg/ml; 24 hours) RPE cells, VU0359595 (5 μM; 1 hour before LPS treatment) modifies the autophagy process [4]. The enhanced internalization of Aspergillus fumigatus in A549 cells caused by 50 ng/ml gliotoxin is blocked by VU0359595 (2 nM; 30 min pretreatment) [5].
VU0359595 (at 5, 50, 500, 5000 nM) inhibits astroglial proliferation at basal levels and in response to FCS/IGF-1 stimulation. It reduces mitogen-stimulated PLD activity in a concentration-dependent manner. It partially reduces high glucose-induced PEth production in retinal pigment epithelial cells and modulates LPS-induced autophagy. |
| ln Vivo |
In vivo, VU0359595 has been used to study its effects on PLD1 activity. Downregulation of PLD1 and exposure to the inhibitor attenuated PLD activity and strongly reduced the mitogenic activity of serum and IGF-1. It blocks gliotoxin-induced internalization in A549 cells. Its role in various disease models is under investigation.
|
| Enzyme Assay |
The primary assay for PLD1 inhibition involves measuring enzyme activity in a cell-free system. PLD1 is incubated with its substrate, and the production of phosphatidic acid or choline is measured. VU0359595's potency is determined by its IC50 value (3.7 nM) in this type of assay.
|
| Cell Assay |
In vitro cellular experiments involve treating cells with VU0359595 and measuring downstream effects of PLD1 inhibition. This includes assessing cell proliferation, measuring changes in PLD activity, and evaluating markers of autophagy and inflammation. High glucose and LPS stimulation models are used to study its protective and modulatory effects.
|
| Animal Protocol |
In vivo studies are conducted to evaluate the effects of PLD1 inhibition by VU0359595. These studies often involve animal models of disease where the compound is administered to assess its impact on disease progression, such as in cancer or inflammation models. Its in vivo efficacy is a key area of research.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for VU0359595 in animals or humans is not extensively reported in the provided sources. As a research compound, its properties are typically evaluated in preclinical studies. Its molecular weight is 497.43 g/mol, and it is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicological data for VU0359595 is not widely available as it is a research compound. It is supplied for research purposes only and is not intended for diagnostic or therapeutic use in humans. Standard laboratory safety practices should be followed.
|
| References |
|
| Additional Infomation |
VU0359595 is a highly selective chemical probe for studying PLD1 function. It is not an approved drug. Its exceptional selectivity (>1700-fold over PLD2) makes it a critical tool for dissecting the specific roles of PLD1 in complex biological systems and disease models.
|
| Molecular Formula |
C25H29BRN4O2
|
|---|---|
| Molecular Weight |
497.427365064621
|
| Exact Mass |
496.147
|
| CAS # |
1246303-14-9
|
| PubChem CID |
44573131
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.631
|
| LogP |
4.71
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
691
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H](CN1CCC(CC1)N2C3=C(C=C(C=C3)Br)NC2=O)NC(=O)[C@@H]4C[C@H]4C5=CC=CC=C5
|
| InChi Key |
JSVNNLRZCJAYTQ-ORYQWCPZSA-N
|
| InChi Code |
InChI=1S/C25H29BrN4O2/c1-16(27-24(31)21-14-20(21)17-5-3-2-4-6-17)15-29-11-9-19(10-12-29)30-23-8-7-18(26)13-22(23)28-25(30)32/h2-8,13,16,19-21H,9-12,14-15H2,1H3,(H,27,31)(H,28,32)/t16-,20-,21+/m0/s1
|
| Chemical Name |
(1R,2R)-N-[(2S)-1-[4-(5-bromo-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]-2-phenylcyclopropane-1-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~20.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0103 mL | 10.0517 mL | 20.1033 mL | |
| 5 mM | 0.4021 mL | 2.0103 mL | 4.0207 mL | |
| 10 mM | 0.2010 mL | 1.0052 mL | 2.0103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
